These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32327165)

  • 21. Totality of the evidence at work: The first U.S. biosimilar.
    Holzmann J; Balser S; Windisch J
    Expert Opin Biol Ther; 2016; 16(2):137-42. PubMed ID: 26634611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim.
    McBride A; Wang W; Campbell K; Balu S; MacDonald K; Abraham I
    J Med Econ; 2020 Aug; 23(8):856-863. PubMed ID: 32323582
    [No Abstract]   [Full Text] [Related]  

  • 23. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
    Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
    Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
    Mansell K; Bhimji H; Eurich D; Mansell H
    BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of a conversion from filgrastim to filgrastim-sndz in stem cell transplant patients undergoing mobilization.
    Curry LD; Anders B; Dressler EV; Kennedy L
    J Oncol Pharm Pract; 2021 Jun; 27(4):871-876. PubMed ID: 32686616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variation in Physician Spending and Association With Patient Outcomes.
    Tsugawa Y; Jha AK; Newhouse JP; Zaslavsky AM; Jena AB
    JAMA Intern Med; 2017 May; 177(5):675-682. PubMed ID: 28288254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done?
    Qureshi ZP; Nagai S; Bennett CL
    JAMA Oncol; 2019 Mar; 5(3):297-298. PubMed ID: 30508013
    [No Abstract]   [Full Text] [Related]  

  • 28. Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population.
    Kozlowski S; Birger N; Brereton S; McKean SJ; Wernecke M; Christl L; Kelman JA
    JAMA; 2018 Sep; 320(9):929-931. PubMed ID: 30193265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
    Socal MP; Ezebilo I; Bai G; Anderson GF
    Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A single-center, retrospective analysis to compare the efficacy and safety of filgrastim-sndz to filgrastim for prophylaxis of chemotherapy-induced neutropenia and for neutrophil recovery following autologous stem cell transplantation.
    Zecchini J; Yum K; Steinberg A; Smith C; Kim S
    Support Care Cancer; 2018 Mar; 26(3):1013-1016. PubMed ID: 28990128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
    Dickson SR; Kent T
    JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilar Use Among 38 ASCO PracticeNET Practices, 2019-2021.
    Bourbeau B; Lyman GH; Lei XJ; Jones L; Rosenthal J; Kozlik MM; Oettel KR; Tinger A; Page R
    JCO Oncol Pract; 2023 Jul; 19(7):516-522. PubMed ID: 37084324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the 340B Drug Pricing Program on Cancer Care Site and Spending in Medicare.
    Jung J; Xu WY; Kalidindi Y
    Health Serv Res; 2018 Oct; 53(5):3528-3548. PubMed ID: 29355925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
    Harbeck N; Gascón P; Krendyukov A; Hoebel N; Gattu S; Blackwell K
    Oncologist; 2018 Apr; 23(4):403-409. PubMed ID: 29317553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program.
    Bond AM; Dean EB; Desai SM
    Health Aff (Millwood); 2023 May; 42(5):632-641. PubMed ID: 37126754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product.
    Mendelsohn AB; Marshall J; McDermott CL; Pawloski PA; Brown JS; Lockhart CM
    Drugs Real World Outcomes; 2021 Jun; 8(2):125-130. PubMed ID: 33517548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biosimilar Uptake In The US: Patient And Prescriber Factors.
    Hong D; Kesselheim AS; Sarpatwari A; Rome BN
    Health Aff (Millwood); 2024 Aug; 43(8):1159-1164. PubMed ID: 39102605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First Pegfilgrastim Biosimilar Approved.
    Aschenbrenner DS
    Am J Nurs; 2018 Oct; 118(10):19-20. PubMed ID: 30260881
    [No Abstract]   [Full Text] [Related]  

  • 39. Real World Clinical Experience of Biosimilar G-CSF (Grastofil) for Autologous Peripheral Blood Stem Cell Mobilization: Single Center Experience in Canada Following Early Adoption.
    Aggarwal V; Sabry W; Elemary M; Bosch M; Danyluk P; Mondal P; Stakiw J
    Curr Oncol; 2021 Apr; 28(3):1571-1580. PubMed ID: 33922026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.
    Ludwig H; Bokemeyer C; Aapro M; Boccadoro M; Gascón P; Denhaerynck K; Krendyukov A; Abraham I; MacDonald K
    Future Oncol; 2019 Mar; 15(8):897-907. PubMed ID: 30827127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.